SCHEMBL23729817

SCHEMBL23729817

O=C(OCCCc1ccncc1)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.56
▸ ALB P02768 1/20 0.56
▸ MAOA P21397 1/20 0.56
▸ CNR1 P21554 1/20 0.56
▸ DRD1 P21728 1/20 0.56
▸ OPRD1 P41143 1/20 0.56
▸ PDE4D Q08499 1/20 0.56
▸ PDE3A Q14432 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.42
▸ NAMPT P43490 1/20 0.40
▸ MAPT P10636 5/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ NFKB2 Q00653 1/20 0.39
▸ RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23729816 0.94 TTR (0.58) TTRALBMAOACNR1DRD1
SCHEMBL23729821 0.89 TTR (0.53) TTRALBMAOACNR1DRD1
SCHEMBL23729823 0.88 TTR (0.61) TTRALBMAOACNR1DRD1
SCHEMBL23704611 0.87 TTR (0.57) TTRALBMAOACNR1DRD1
SCHEMBL30163134 0.86 TTR (0.63) TTRALBMAOACNR1DRD1
SCHEMBL24928448 0.86 TTR (0.63) TTRALBMAOACNR1DRD1
SCHEMBL23729867 0.85 TTR (0.63) TTRALBMAOACNR1DRD1
SCHEMBL23729408 0.85 TTR (0.62) TTRALBMAOACNR1DRD1
SCHEMBL28737921 0.85 PDE4D (0.62) TTRALBMAOACNR1DRD1
SCHEMBL29573317 0.85 PDE4D (0.62) TTRALBMAOACNR1DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. 2023-09-14 — — US disclosed
WO-2021154842-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING PROTEGO BIOPHARMA, INC. (US) 2021-08-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230287021-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING TTR, TTPA, TNNC1 TTR 1/4885ALB 8/4885MAOA 3300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback